BURLINGTON, Vt. -- Triosyn Corp., a developer of products aimed at protecting against microbial threats, announced today that tests conducted by Health Canada's National Microbiology Laboratory show that Triosyn T-1000 Series Respirators protect against Severe Acute Respiratory Syndrome (SARS). The third-party tests, which validate Triosyn's extensive testing, demonstrate that Triosyn's unique filtration technology eliminates SARS viral particles from the air passing through the facemask.
Health Canada, the Canadian federal bureau of health, conducted
independent testing on the efficacy of Triosyn's facemask filter to protect
against SARS coronavirus, the viral agent responsible for SARS. The test
involved blowing air contaminated with the SARS coronavirus through the
facemask and analyzing the airstreams that passed through the facemask for the
presence of viral particles. Tests were conducted at three different exposure
periods: 15, 60 and 120 minutes. Health Canada's test results show that no
coronavirus particles were detected in the airstreams that passed through the
Triosyn T-1000 Series Respirator during any of the three different exposure
periods.
"Health Canada's tests confirm that the T-1000 is the world's first
personal facemask that can provide protection against the potentially deadly
airborne SARS virus," said Pierre Jean Messier, CEO of Triosyn Corp. "Police forces in North America are currently using the T-1000
facemask and we are introducing it throughout the world."
SARS is a potentially deadly respiratory virus which currently has no
vaccine. More than 8,400 people in 29 countries have contracted SARS and more
than 900 people have died worldwide since the emergence of SARS in November
2002. The World Health Organization states that the virus can be transmitted
through the air, via coughing or sneezing, on tiny droplets of bodily fluids.
The Triosyn T-1000 Respirator, a disposable personal facemask manufactured
with an innovative antimicrobial technology to protect the filtration
materials from microbial deterioration, is certified by the National Institute
for Occupational Safety and Heath (NIOSH) as an N95 filtering facepiece
respirator. It is also CE certified in Europe.
Source: Triosyn Corp.
Unraveling a Candida auris Outbreak: Infection Control Challenges in a Burn ICU
March 19th 2025A Candida auris outbreak in a burn intensive care unit (BICU) in Illinois has highlighted the persistent challenges of infection control in high-risk health care settings. Despite rigorous containment efforts, this multidrug-resistant fungal pathogen continued to spread, underscoring the need for enhanced prevention strategies, environmental monitoring, and genomic surveillance.
Unmasking Long COVID: Dr Noah Greenspan on Recovery, Research Gaps, and the Future of Treatment
March 18th 2025Dr Noah Greenspan discusses the evolving understanding of long COVID, current treatment strategies, diagnostic challenges, and the critical need for research and awareness in post-viral syndromes.
From Shortages to Security: How Reusable Health Care Textiles Can Transform Infection Prevention
March 7th 2025Reusable health care textiles enhance infection prevention, reduce waste, and strengthen supply chains. Hygienically clean textiles offer a sustainable, cost-effective alternative to disposable PPE, ensuring patient safety and environmental responsibility.